Last $1.08 USD
Change Today -0.18 / -14.29%
Volume 1.4M
ENZN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Richard C. Mulligan Ph.D.

Independent Director, Chairman of Science & Technology Committee and Member of Compensation & Management Development Committee, Biogen Idec Inc.
AgeTotal Calculated CompensationThis person is connected to 10 board members in 1 different organizations across 5 different industries.

See Board Relationships
59$361,548

Background*

Prof. Dr. Richard C. Mulligan, Ph.D., serves as a Consultant of DuPont, Genetics Institute and AMGEN. Prof. Dr. Mulligan is the Founder of Somatix Therapy Corporation and served as its Chief Scientific Officer. He served as Vice Chairman of the Board of Managers of Kadmon Pharmaceuticals LLC. Prof. Dr. Mulligan served as the Vice Chairman of Enzon Pharmaceuticals Inc. from March 17, 2011 to November 20, 2013 and its Director from 2009 to November 20, 2013. He serves ...

Read Full Background

Corporate Headquarters*

20 Kingsbridge Road
Piscataway, New Jersey 08854

United States

Phone: 732-980-4500
Fax: --

Board Members Memberships*

Former Independent Director
Former Vice Chairman of the Board of Managers
2006-2008
Former Director, Member of Audit Committee, Member of Executive Committee, Member of Nominating & Corporate Governance Committee and Member of Research & Development Oversight Committee
2009-Present
Independent Director, Chairman of Science & Technology Committee and Member of Compensation & Management Development Committee
2009-2013
Former Vice Chairman and Chairman of Governance & Nominating Committee

Education*

BS
Massachusetts Institute of Technology
Post-Doctoral Training
Massachusetts Institute of Technology
PhD
Stanford University School of Medicine

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$92,000
Total Calculated Compensation$361,548
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $1.08 USD -0.18

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Marc N. Casper Chief Executive Officer, President, Director, Member of Strategy & Finance Committee and Member of Science & Technology Committee
Thermo Fisher Scientific, Inc.
$1.1M
Robert J. Hugin MBAChairman, Chief Executive Officer and Chairman of Executive Committee
Celgene Corporation
$1.3M
Lars Rebien Sørensen Chief Executive Officer
Novo Nordisk A/S
kr15.2M
Flemming Ornskov M.D., MBA, MPHChief Executive Officer, Managing Director and Director
Shire plc
$2.7M
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.